Given the Republic of Korea’s implementation of an expansive new anti-corruption law, its increasingly strong enforcement of that law and other related laws, as well as the possibility of enforcement of foreign anti-corruption regimes like the FCPA in Korea, companies doing business there would do well to ensure their compliance programs are robust. One particular industry of concern in the region is life sciences. In a guest article, Ropes & Gray attorneys Mimi Yang, Karen Oddo and Yaping Zhang discuss the current enforcement environment in Korea, the risks companies in the life-sciences space face and what actions those companies need to take to ensure compliance with local requirements. See “GSK SEC Settlement Highlights Multi-Jurisdictional Enforcement Risk” (Oct. 12, 2016).